FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc. today announced it has been awarded a contract from the Division of Research, Innovation, and Ventures (DRIVe), under the Biomedical Advanced ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
Chemo-praidict eBC: A deep learning solution for predicting pathological complete response on biopsies of breast cancer patients treated with neoadjuvant chemotherapy. Big data analysis of outcomes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results